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Human
YeastHsp90 is an essential chaperone for more than 200 client proteins in eukaryotic cells. The human genome
encodes two highly similar cytosolic Hsp90 proteins called Hsp90α and Hsp90β. Most of the client proteins
can interact with either Hsp90 protein; however, only a handful client proteins and one co-chaperone that
interact speciﬁcally with one of the Hsp90 isoforms were identiﬁed. Structural differences underlying these
isoform-speciﬁc interactions were not studied. Here we report for the ﬁrst time that the Hsp90 co-chaperone
Aha1 interacts preferentially with Hsp90α. The distinction depends on themiddle domain of Hsp90. The middle
domain of Hsp90α is also responsible for the slow growth phenotype of yeasts that express this isoform as a sole
source of Hsp90. These results suggest that differences in the middle domain of Hsp90α and Hsp90βmay be
responsible for the isoform-speciﬁc interactions with selected proteins. Also shown here within, we determine
that preferential chaperoning of cIAP1 by Hsp90β is mediated by the N-terminal domain of this isoform.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The 90-kDa heat shock protein (Hsp90) is an essential chaperone
in eukaryotic cells [1]. Hsp90 structure is composed of three distinct
domains: N-terminal ATPase domain (N-domain), middle domain
(M-domain) that contains the major site of the interaction with client
proteins, and C-terminal domain (C-domain) responsible for Hsp90 di-
merization [2–5].
In the human genome, there are two genes that encode the 86%
identical cytoplasmic proteins (isoforms) called Hsp90α and Hsp90β
(also named Hsp90AA1 and Hsp90AB1). Together, these isoforms con-
stitute up to 2% of total cellular protein [6], but the ratio between the
isoforms varies signiﬁcantly in different tissues and cell lines [7,8].
Most tissues express both isoforms, but Hsp90β is usually more abun-
dant, except for the brain and the oocytes [9,10]. Hsp90α is thought to
be more inducible than Hsp90β under stress conditions [11,12].
However, in human kidney cells, transcription of both isoforms can be
equally induced under stress [13]. In solution, Hsp90α exists as a
dimer, whereas Hsp90β can be found both as a dimer and monomer
[14,15]. Despite high sequence identity, noheterodimers of the isoforms
were observed [16].
Hsp90 interacts with more than 200 client proteins [17,18]. Most of
these proteins are thought to be chaperoned by both Hsp90 isoforms.ygeldanamycin; aa, amino acid;
wski).Relatively few examples, listed below, of a preferential interaction of a
client protein with one Hsp90 isoform or isoform-speciﬁc function
were reported. Hsp90α, for example, is indispensable for the antigen
processing necessary to generate peptide-loaded MHC I complexes, for
spermatocyte maturation and for maturation of the hERG ion channel
[19–21]. Hsp90α can be secreted to the extracellular matrix, where it
plays a vital role in cancer metastasis by regulating metalloproteinase
activity [22]. Mouse knockout studies demonstrated that Hsp90β is re-
quired for the proper formation of placenta [23]. Several proteins such
as cIAP1 and vitamin D receptor were shown to interact preferentially
with Hsp90β [24,25]. Hsp90β is also involved in the response of macro-
phages and dendritic cells to bacterial DNA [26]. It was also reported
that Hsp90α and Hsp90β have opposing effects on endothelial nitric
oxide synthase (eNOS) activity. Nitric oxide production by eNOS is
stimulated by overexpression of Hsp90α but inhibited by Hsp90β, a
property that was attributed to the higher stability of Hsp90α dimers
[27]. Hsp90α and Hsp90β have also the opposite effect of on the
biogenesis of KCNQ4 channels [28].
Hsp90 function is regulated by numerous co-chaperone proteins.
Co-chaperones help Hsp90 to form complexes with client proteins
and regulate Hsp90 ATPase activity [29]. The only known example
of an isoform-speciﬁc co-chaperone is Gcunc45 that interacts preferen-
tially with the Hsp90β [30]. A complete list of Hsp90 interacting
proteins with references can be found at www.picard.ch/downloads.
html
No studies on the structural features of human Hsp90s underlying
isoform speciﬁcity have been reported to date. Therefore, we decided
to investigate which fragments of human Hsp90 may be responsible
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Aha1 and the client protein cIAP1.
2. Methods
2.1. Plasmids construction
Plasmids for the expression of human Hsp90α and β genes in yeast
and plasmids for expression in human cells that contain Hsp90 genes
fused to the N-terminal Flag-HA tags were described previously [31].
These plasmids served as templates in the PCR reactions to create frag-
ments used to construct hybrid Hsp90 genes containing fragments of
the Hsp90α and Hsp90β isoforms. Hsp90 hybrids were constructed by
a two-step PCR. Fragments of the Hsp90α and Hsp90β were ampliﬁed
using primers that created 30–40 bp overlaps at the junction site.
These fragments served as templates in an overlap extension PCR with
primers that added 25 bp sequences homologous to the polylinkers of
the cloning vectors [32]. Hybrid Hsp90 used to create yeast expression
vectors were created using wild-type Hsp90α and Hsp90β sequences.
Hybrids used in experiments in human cells were made of genes that
contained a single amino acid substitution, Hsp90α Ile128Thr and
Hsp90β Ile123Thr.
Construction of the plasmid p423TDH3 was described previously
[31]. Hsp90 genes for expression in yeast were cloned into plasmid
p423TDH3 digested with enzymes SpeI and SmaI. Plasmids used for
human cell transfection were made by cloning of the Hsp90 genes in
the plasmid pcDNA3.1 digested with enzymes KpnI and XhoI. The ﬁnal
PCR products containing complete hybrid Hsp90 genes were inserted
into vectors digested with the indicated above restriction enzymes
using cohesive ends generated with T4-polymerase as described earlier
[33].
Details on the created Hsp90 hybrids are provided in Fig. 1 and
Supplementary Fig. 1.
The open reading frame of the human cIAP1 was cloned in the plas-
mid pcDNA3.1. Point mutations in the Hsp90 were generated by PCRFig. 1. Diagram of Hsp90 hybrid genes used in this work. Sequences of Hsp90α labeled in gray,
tions of the fragments used to create hybrid sequences.with mutagenic primers [32]. Oligonucleotides used in this study are
listed in Supplementary Table 1. Hsp90 alleles with Ile128Thr and
Ile123Thr mutations, which were used in experiments with HEK-293
cells, were marked in the text with superscript IT, to distinguish them
from the wild-type alleles used in experiments in yeasts.2.2. Yeast strains and yeast growth assays
Saccharomyces cerevisiae strain used in this study had genotype ade2
ura3 trp1 leu2 his3 lys2MATa hsc82::G418 Hsp82::G418. Both endoge-
nous Hsp90 genes were replaced in this strain with G418 markers. The
strain carried the plasmid with Ura3-selective marker and human
Hsp90α gene expressed from the TDH3 promoter. The construction of
this strain was described previously [31]. This strain was transformed
with plasmids containing different Hsp90 genes and a His3 marker.
The obtained HIS3+ transformants were selected for loss of Ura3-
based plasmid in medium containing 0.1% 5' ﬂuoroorotic acid [34].
The constructed strains that expressed human Hsp90α and Hsp90β
were named BY561 and BY562, respectively.
Strains BY561 and BY562 were used to construct mutants in which
AHA1 and HCH1 open reading frames were replaced with TRP1 gene.
DNA fragments used for the gene replacement were ampliﬁed by PCR
with primers listed in Supplementary Table 1 using plasmid pRS414 as
a template. Yeasts were transformed with these PCR products, and
transformants were selected on plates with medium lacking trypto-
phan. Successful replacement of AHA1 and HCH1 coding sequences
with TRP1 marker was conﬁrmed by PCR with test primers listed in
Supplementary Table 1.
For the growth assays, yeast strains were cultured in YPD medium
supplemented with 100 mg/l of adenine and uracil. The density of the
saturated cultures was adjusted to equal OD600 and a series of dilutions
made from the adjusted culturedwere spotted on YPD-agar plates incu-
bated at 30 °C. The growth of BY561 and BY562 strains and the strains
with additional disruptions of AHA1 and HCH1 genes were monitoredsequences of Hsp90β labeled in white. Numbers indicate amino acid residues at the junc-
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liquid YPD supplemented with 100 mg/l of adenine and uracil at 30 °C.
2.3. Culture and transfection of human cells
HEK-293 cells were cultured in Iscove's modiﬁed Dulbecco's medi-
um (IMDM). Cells were transfected using Lipofectamine 2000 according
to the manufacturer's instructions (Life Technology). After transfection
with 17-AAG-resistant Hsp90 variants (mutants Ile128Thr in Hsp90α
N-domain and corresponding Ile123Thr in Hsp90β N-domain), cells
that express high level of transfected Hsp90 proteins were selected in
IMDMmedium supplemented with 1 μM 17-AAG, 10% calf serum, and
a standard penicillin–streptomycin solution. During selection, cells
were trypsinized and passaged to fresh culture plates in 1 μM 17-AAG
every 2–3 days. Control cells transfected with the pcDNA3.1 vector
were treated identically to monitor the process of selection.
2.4. Immunoprecipitations
Immunoprecipitation of Flag-tagged Hsp90
For immunoprecipitation, cells were grown to about 70% conﬂuency
in 10 cm culture dishes. Immunoprecipitation was performed using
anti-Flag antibodies covalently linked to agarose beads (Sigma-Aldrich).
Cells were lysed at 70–90% conﬂuency in 1 ml of buffer containing
25 mM Tris pH 7.6, 1 mM ATP, 0.5% Triton X-100, and protease and
phosphatase cocktails (Roche). Insoluble debris was removed by centri-
fugation for 15 min at 14 000 rpm. Cleared lysate was incubated with
antibody-coupled beads (20 μl volume) at 4 °C for 2 h with constant
mixing. Beads were washed three times with 25 mM Tris pH 7.6.
Bound proteins were eluted with 1% SDS and analyzed by western blot.
Immunoprecipitation of wild-type Hsp90
Seventy percent conﬂuent HEK-293 cells cultured in 10 cm plates
were transfected with N-terminally tagged with FLAG sequence
Hsp90α and Hsp90β genes cloned in pcDNA3.1 plasmid [31]. Cells
were cultured in IMDM medium supplemented with 10% serum and
standard penicillin–streptomycin solution, without 17-AAG for 48 h be-
fore immunoprecipitation experiment. Lysis was performed in 1 ml of
lysis buffer described above except for ATP that was replaced with
5 mM non-hydrolyzable ATP analog 5′-adenylylimidodiphosphate
(AMPPnP). Immunoprecipitation was performed as described above.
2.5. Chaperoning activity of hybrid Hsp90s for cIAP-1
HEK-293 cells that stably expressed Hsp90 17-AAG-resistant variants
of hybrid Hsp90 proteins were transfected with the cIAP1 gene fused
to c-terminal Myc-tag cloned in pcDNA3.1 plasmid using GeneCellin
according to the manufacturer's instructions (BioCellChallenge).
Transfected cells were cultured in medium without antibiotics.
Twenty-four hours after transfection, the cells were harvested, lysed
in buffer containing 25mMTris, pH 7.6, 0.5% Triton X-100, and cocktails
of protease and phosphatase inhibitors (Roche). Lysates were centri-
fuged at 14000 rpm for 10 min. Protein concentration was measured
using BCA assay (Pierce). Equal amounts of protein for each sample
were loaded on the gel.
The antibodies used for western blot analysis were as follows:
FLAG (Sigma-Aldrich, F3165), Aha1 (Abcam, ab56721), Cdc37
(Abcam, ab109419), Hsp90β (Abcam, ab119833), actin (MP Biomedi-
cals #69100), and Myc-Tag (Cell Signaling, 71D10)
3. Results
3.1. Analysis of the hybrid human Hsp90s activity in yeasts
Each of the human Hsp90 can replace both yeast homologues, but
cells that express only Hsp90α grow much slower than cells that ex-
press only Hsp90β [35]. We reasoned that this difference may be usedto identify structural differences in the human Hsp90 isoforms. Hence,
we created a number of yeast strains that expressed point mutants of
human Hsp90 or Hsp90 hybrids composed of fragments of human
Hsp90α and Hsp90β as a sole form of this protein. Growth rate of these
strains was correlated with the structural features of the expressed
Hsp90 proteins.
3.2. Dimerization is not a major factor in isoform differences
Hsp90 chaperone acts as a homodimer. Dimers formed by the
Hsp90α are more stable than dimers of Hsp90β, which may inﬂuence
the activity of the isoforms. Therefore, we decided to test whether activ-
ity of the humanHsp90 isoforms in yeasts correlateswith their ability to
dimerize. Substitution of alanine 629withmethionine decreases dimer-
ization of Hsp90α, whereasmutationMet621Ala in Hsp90β stabilizes di-
mers of this isoform [36]. We constructed yeast strains that expressed
Hsp90 with these amino acid (aa) substitutions and compared their
growth with that of the control strains that expressed wild-type
human Hsp90α or Hsp90β. Results presented in Fig. 2A demonstrate
that growth rates of themutant strainswere similar to those of controls,
indicating that stability of the dimers is not a major factor in different
ability of the isoforms to support growth of yeasts.
3.3. Differences in Hsp90 isoforms activity are caused by differences in the
M-domain structure
We hypothesized that growth phenotype of the yeasts that express
human Hsp90 depends on structural differences located in particular
domain of this protein. To test this hypothesis, we constructed a number
of hybrid Hsp90 genes in which the fragments that encode N-, M-, or C-
domains of the Hsp90α sequence were substituted with the corre-
sponding sequences of Hsp90β (Fig. 1). We created also hybrids H9
and H10 in which charged linker regions (aa 220-278 in Hsp90α and
aa 215-270 in Hsp90β), the most divergent fragments of the human
Hsp90α/β, were swapped. The hybrids H13 and H14 with swapped
sequences of the N-terminal ends were also constructed because of
the involvement of these sequences in the N-domain dimerization es-
sential for Hsp90 activity [37]. Plasmids carrying these hybrids were
transformed into yeast cells to replace an original plasmid with the
human Hsp90α. Yeasts expressing hybrids with only a small fragment
of Hsp90α or Hsp90β replaced (H9, H10, H13, and H14) grew at similar
rate as the control strains that expressed native Hsp90α or Hsp90β,
respectively (Fig. 2B). Therefore, we concluded that the fast/slow
growth phenotype was not affected by the replacement of the charged
linker region or the N-terminal fragment of the N-domains.
The remaining transformants could be divided into two groups
clearly differing in their growth rates. Fast growing strains expressed
Hsp90β or hybrids H3, H6, H7, whereas slow growing strains were
transfected with Hsp90α or hybrids H4, H5, H8 (Fig. 2C). These results
demonstrated that the fast growth of yeast cells correlated with the
presence of the middle domain of the Hsp90 β in the analyzed hybrid
gene. To narrow down this region, we analyzed hybrids in which only
half of the middle domain was replaced (H11 and H12). The yeasts
transformed with the hybrid H11, composed of Hsp90α with the C-
terminal part of the middle domain replaced with the respective
Hsp90β sequence, demonstrated fast growth phenotype, whereas the
H12 hybrid composed of Hsp90β sequence and the C-terminal fragment
of the Hsp90α middle domain conferred slow growth phenotype
(Fig. 2C). In an attempt to identify residue(s) responsible for the slow
growth phenotype of yeasts expressing H12, we constructed two addi-
tional hybrids (H15 and H16). Each of these hybrids contained only half
of the Hsp90α sequence present in theH12 hybrid. Results presented in
Fig. 2C demonstrate that growth of the yeasts that expressed H15 and
H16 is comparable to the control strain that expresses wild-type
Hsp90β. These results indicated that the yeast growth rate was
Fig. 2. Growth assay of yeasts that express Hsp90 hybrids and mutants. Saturated yeast cultures were diluted to equal optical density. Aliquots (2 μl) from the series of 2-fold dilutions
(panels A, B and D) or 4-fold dilutions (panel C) of yeast cultures expressing indicated Hsp90 hybrids or Hsp90 mutants were spotted on YPD plates and incubated at 30 °C. Hybrids
that contain amino acids 380–560 of Hsp90α on panel C are marked with an asterisk (*). Presented are results of one of three experiments.
448 K. Synoradzki, P. Bieganowski / Biochimica et Biophysica Acta 1853 (2015) 445–452determined by the overall structure of the c-terminal half of the human
Hsp90 M-domain rather than by the single aa changes.
3.4. M-domain of Hsp90α binds Aha1 with high afﬁnity
Published results suggest that Aha1 co-chaperone may bind to
Hsp90α stronger than it does to Hsp90β [18,31]. This observation was
conﬁrmed by the results of the co-immunoprecipitation presented in
Fig. 3a. Therefore, we attempted to attribute this difference to a speciﬁc
region of the Hsp90 using hybrid Hsp90 genes. To this end, we con-
structed Hsp90 hybrids with a single aa substitution, namely, Ile128Thr
in Hsp90α and the corresponding Ile123Thr in Hsp90β, which renders
Hsp90 insensitive to compounds targeting ATP-binding pocket, such
as geldanamycin or 17–AAG [31]. Hsp90 activity depends strictly on
ATP hydrolysis. Cells transfected with the inhibitor-resistant mutant
can be cultured in a presence of the 17-AAG. In such cells, endogenous
Hsp90 should be inactive and the Hsp90 activity should come solely
from the transfected Hsp90 protein. This inhibition of the endogenous
Hsp90 allowed study of the transfected Hsp90 activity, without using
standard gene-silencing techniques. To test whether the formation of
heterodimers between native and transfected Hsp90 proteins could in-
ﬂuence observed results, we compared expression ratio of the endoge-
nous Hsp90β and FLAG-tagged Hsp90β I123T in the cells after 17-AAG
selection and the composition of the complexes immunoprecipitated
from these cells using anti-FLAG antibody. Similar to the previously
published results [31], we found native and mutant proteins were
expressed at the similar level, but the complexes isolated by the immu-
noprecipitation were composed predominantly of the tagged mutant
protein Fig. 3b. Therefore, we concluded that heterodimerization of
the native and mutant Hsp90 proteins should not pose substantial
problem in the analysis of the mutant Hsp90.
HEK-293 cells transfected with different variants of the Hsp90
genes were selected using 17-AAG. The 17-AAG-resistant clones that
expressed transfected Hsp90 were obtained in each case. This con-
ﬁrmed that all Hsp90 hybrids were functional. It has been shown previ-
ously that human Hsp90α/β hybrids with swapped N-domains are
functional in yeast [38]. Our results proved that each domain of the
human Hsp90 can be replaced with its homolog from the other isoformto create a functional protein. The 17-AAG toxicity was similar for all
tested transfectants. IC50 values for all transfectants exceeded 2 μM,
whereas control cells transfected with empty vector were unable to
grow in 0.25 μM17-AAG.We used 1 μM17-AAG for the subsequent ex-
periments because at this concentration all transfectants grew at a rate
similar to the control cells grown in medium without 17-AAG and the
cells maintained expression of the transfected Hsp90 even during
prolonged culture (Supplementary Fig. 2).
Co-immunoprecipitation results indicated that differences in Aha1
binding to Hsp90 were determined by the M-domain of Hsp90
(Fig. 4A). Every Hsp90 protein that contained the Hsp90α M-domain
bound more Aha1 than Hsp90 that contained the Hsp90βM-domain.
We also tested the binding of Cdc37, another Hsp90 co-chaperone,
to hybrid Hsp90 proteins. Cdc37 bound to all the hybrids with no clear
preference toward any particular isoform (Fig. 4A).
Results of our analysis of Hsp90 hybrids in yeasts suggested that C-
terminal part ofM-domainmay discriminate between humanHsp90 iso-
forms. Therefore, we looked for aa differences in this region of Hsp90α
and Hsp90β that could inﬂuence binding of Aha1 (Supplementary
Fig. 1). The structure of the yeast Aha1 complex with the middle domain
of Hsp90 suggests that only one of these residues, Glu454 in Hsp90α
(corresponding to Thr446 in Hsp90β), is located at the Hsp90-Aha1 inter-
face. This residue is homologous in the yeast Hsp82 sequence to Glu434
that interacts directly with Glu108 in the Aha1 [39]. However, results
presented in Fig. 2D demonstrated that growth rates of the strain that
expressed Hsp90α Glu454Thr mutant and of the control strain expressing
the wild-type Hsp90αwere similar.
3.5. Human Hsp90s require Aha1, but not Hch1, for the full activity in
yeast cells
Wehypothesized, based on the results of co-immunoprecipitation in
human cells, that human Hsp90 isoforms may interact differently with
the yeast homologues of human Aha1, named Aha1 and Hch1 [40,41].
To test this hypothesis, we tested the effect of the deletion of AHA1
and HCH1 genes on the growth of the strains BY561 and BY562 that
expressed one of the human Hsp90 proteins. Results presented in
Fig. 5 demonstrated that disruption of HCH1 and AHA1 had very little
Fig. 3. Aha1 binds Hsp90α with higher afﬁnity. (A) Hek 293 cells were transfected with
plasmids that expressed wild-type Hsp90α and Hsp90β fused to N-terminal Flag tag. Im-
munoprecipitation was performed with Flag-speciﬁc antibody 48 h after transfection.
Aha1 was detected in precipitates normalized for equal amount of Hsp90 protein. Con-
trol—immunoprecipitation made from the cells transfected with empty vector. (B) Hek
293 cells were transfected with plasmid that expressed Hsp90β I123T. Transfectants
were selected for resistance for 17-AAG. Immunoprecipitation with anti-FLAG antibody
was performed using cells that were cultured in a presence of 1 μM 17-AAG. Lines are la-
beled as follows: Ctr—lysate from the HEK 293 cells not transfected and not treated with
17-AAG; IP—sample after immunoprecipitation; Lo—lysate used as a load for the immuno-
precipitation.Western blotwasdetectedwith antibody speciﬁc forHsp90β. PanelsA andB
presents results of one of two independent experiments.
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the strain that expressed Hsp90α was compromised by the disruption
of the AHA1 gene, but not by the disruption of the HCH1 gene.
3.6. Hsp90 client protein cIAP1 interacts preferentially with the N-domain
of Hsp90β
We reasoned that a substrate protein preferentially chaperoned by
one Hsp90 isoform may interact differently with the Hsp90 hybrids
allowing for identiﬁcation of the Hsp90 region responsible for isoform
speciﬁcity. We tested this hypothesis using as a model cIAP1 protein
that is chaperoned by Hsp90β, but not Hsp90α [24]. Results presented
in Fig. 4B demonstrate that cells transfected with the HSP90 gene that
contained the N-domain of HSP90β express more cIAP1 than cells
transfected with HSP90 that contained the N-domain of HSP90α.
4. Discussion
Most client proteins are believed to interact equally well with both
human cytoplasmic Hsp90 isoforms, but some reports provide evidence
for distinct roles for Hsp90α and Hsp90β in chaperoning of several
proteins. Studies of speciﬁc functions of Hsp90 α and β isoforms in
living cells using methods based on mRNA silencing are hindered by
high expression and stability of these proteins. Therefore, even whenmRNA for Hsp90 is eradicated, some residual level of the protein may
remain. Another problem is posed by unequal expression level of
Hsp90α and Hsp90β. Silencing of the prevalent isoform may have a
stronger effect on the client protein simply because of the depletion of
the total cellular Hsp90 pool rather than due to isoform-speciﬁc interac-
tions. Despite this bias, some preferential interactions of client proteins
with one Hsp90 isoform were conﬁrmed [21,24,25,27,28,30]. However,
at the molecular level, the structural bases for the observed speciﬁcity
were not studied.
In this work, we exploited the differences in the capacity of human
Hsp90 α and Hsp90β for supporting growth of yeast cells to identify
structural features responsible for isoform speciﬁcity. Growth assays
of the yeasts expressing hybrid Hsp90 genes composed of swapped
Hsp90α and Hsp90β fragments demonstrated that themajor difference
between theHsp90 isoforms is related to a small fragment of themiddle
domain. The slowgrowth phenotype associateswith the presence of the
aa 380-560 of Hsp90α in the hybrid. The corresponding fragment of the
Hsp90β (aa residues 372-552) confers fast growth phenotype. It is
worth to note that this fragment contains arginine residue crucial for
theHsp90 ATPase activity (Arg400 in Hsp90α). However, Arg400 is locat-
ed in the loop that is strictly conserved in both human Hsp90 isoforms.
Moreover, direct involvement of this structure in the isoform's differ-
ences is unlikely because Hsp90α and Hsp90β have similar ATP hydro-
lytic activity in vitro [42]. All non-conserved residues in the fragment
sufﬁcient for the change of the yeast growth rate are located in the
124 aa long fragment between aa 416 and 540 in Hsp90α (aa 408-532
in Hsp90β). The structure of M-domain is composed of two distinct do-
mains with the αβα fold connected by three α-helical fragments [2].
The fragment of human Hsp90 identiﬁed in our yeast growth assays as
sufﬁcient and necessary to confer slow growth phenotype constitute
smaller, C-terminal,αβα domain andα-coils connectingαβα domains.
It is likely that the same structure is responsible for the isoform-speciﬁc
differences in interaction with Aha1. Sequences of human Hsp90 are
80% identical (and 89% similar) in this region and differ in only 25 aa
residues. Detailed structural data for the human Hsp90 proteins are
not available. It is therefore difﬁcult to speculate why these subtle
differences signiﬁcantly impact Hsp90 activity.
Hsp90 undergoes extensive post-translationalmodiﬁcations, such as
phosphorylation, acetylation, S-nitrosylation, and ubiquitination [43].
Some of them were shown to modify Hsp90–Aha1 interaction. Phos-
phorylation of Hsp90α on Tyr38 and SUMOylation of Lys191 stimulates
Aha1 binding, whereas acetylation of Lys294 on Hsp90α decreases
Aha1 binding [35,44,45]. The inﬂuence of these modiﬁcations on
Hsp90β activity was not studied. The modiﬁed residues are conserved
in human Hsp90β (Tyr33, Lys186, and Lys286) and in both yeast Hsp90
(Tyr24, Lys178, and Lys270), and the effects of the modiﬁcations at these
residues are similar in both species, which makes them an unobvious
target of isoform-speciﬁc post-translational modiﬁcations. However,
the possibility of the existence of regulatory mechanisms that result in
differential modiﬁcations of these residues cannot be excluded. Recent-
ly, it was demonstrated that expression of constitutively active met and
v-src leads to increased SUMOylation of Hsp90 [45]. One might specu-
late, by analogy to this observation, that isoform-speciﬁc regulation of
the post-translational modiﬁcations is based on Hsp90 interaction
with co-chaperones, or on Hsp90 preference for client proteins.
The only known post-translational modiﬁcation restricted to one
human isoform is phosphorylation of Hsp90α on Thr5 and Thr7 because
these residues have no homologues in the Hsp90β [46,47]. Our experi-
ments excluded the possibility that these modiﬁcations are responsible
for the growth differences in yeast. The sequence comparison of
Hsp90α aa fragment 416–540 and the corresponding fragment of
Hsp90β suggest several residues that are not conserved in other isoform
and that could be a subject of an isoform-speciﬁc post-translational
modiﬁcation. The most likely candidates are Lys457, Lys456, Lys478, and
Thr466 in Hsp90α and Thr446, Thr467, Thr479, Ser470, and Ser482 in
Hsp90β. Whether modiﬁcations of any of these sites in human cells
Fig. 4.Aha1 binds preferentially to Hsp90αM-domain, and cIAP1 is chaperonedmore efﬁciently by Hsp90βN-domain. (A) Hek 293 cells transfectedwith the indicated Hsp90 alleles that
carried mutation I123T or I128T and the N-terminal FLAG peptide were selected for 17-AAG resistance. Lysates made of cells that stably express indicated Hsp90s were
immunoprecipitated with anti-Flag Ab. Control represents IP made from the Hek 293 cells transfected with plasmid pcDNA3.1 and selected for resistance to G418. Aha1 and Cdc37
bound to Hsp90 was detected using speciﬁc antibodies. Presence of the αM-domain in the transfected Hsp90 gene is marked with an asterisk (*). (B) Cells transfected and selected as
in panel A were transfected with second plasmid that carried cIAP1 gene fused to the c-terminal myc-tag. CIAP1 expression was detected in lysates 48 h after transfection. Hybrids
that contain Hsp90β N-domain are marked with ♦. Figures show results of one of two independent experiments.
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domain that change its afﬁnity for Aha1 remains an open question.
However, to explain the different genetic interaction of Aha1 with
human Hsp90 isoforms in yeast by post-translational modiﬁcations
it is necessary to assume that yeasts are capable of the isoform-
speciﬁc modiﬁcations of the human Hsp90 the same way human
cells are. Moreover, this mechanism would have to evolve indepen-
dently in both species (or their ancestors) because the last common
ancestor of yeast and humans had only one Hsp90 gene, and pairs of
Hsp90 genes in humans (Hsp90α and Hsp90β) and S. cerevisiae
(Hsc82 and Hsp82) evolved as a result of independent duplications
[48]. Such parallel evolution is unlikely. Therefore, Hsp90 isoform-
speciﬁc effects in yeast are more easily explained by differences in
the aa composition and structural differences of Hsp90α and
Hsp90βM-domain.
Aha1 stimulates ATP hydrolysis by the N-domain of Hsp90 and acti-
vates the chaperoning activity of Hsp90 [49]. It was previously shown
that both the M- and N-domains of Hsp90 contribute to its interaction
with Aha1 [41,50]. Our results demonstrate that in human cells Aha1
binds stronger with the Hsp90 hybrids that contained the M-domain
of Hsp90α. It was shown previously that Kd for ATPase stimulation by
Aha1 is 3.5-fold lower for Hsp90α compared to Kd for Hsp90β, but
Vmax for Hsp90β is 2-fold higher than Vmax for Hsp90α [42]. The higher
Vmax for Hsp90βmost likely led to the underestimation of Kd value for
this isoform because Aha1 binding to Hsp90 was measured indirectly
by ATPase hydrolysis. Therefore, the real value of Kd for Aha1 bindingto Hsp90α may be 7-fold lower than Kd for Hsp90β. The response of
Hsp90α and Hsp90β to changes in Aha1 concentration may be inﬂu-
enced by their differing afﬁnity for Aha1. This regulatory mechanism
may be important when Aha1 expression changes under stress condi-
tions or as a result of regulation by other proteins [49,51].
We used Hsp90 alleles with N-domain mutations that increase the
resistance of Hsp90 to inhibitors such as 17-AAG in experiments in
HEK-293 cells. By culturing the transfected cells in medium containing
17-AAG, we were able to select population of the cells that expressed
transfected Hsp90 at very high level, matching that of the endogenous
Hsp90 [31]. Moreover, the inhibitor inactivated dimers composed of
the endogenous Hsp90, leaving protein expressed from the transfected
gene as the only functional Hsp90 in the cell. However, heterodimers
composed of the native and transfected Hsp90 could form even in the
presence of the inhibitor. We did observe such heterodimers, but they
constituted a minor fraction of the immunoprecipitated complexes.
Most of the Hsp90 dimerswere composed of two subunits of the tagged
Hsp90 expressed from the transfected plasmid. Hsp90 dimerization is
driven primarily by the C-domains. However, changes in ability of the
N-domains to bind ATP and to adopt closed conformation affect stability
of Hsp90 dimers [52]. Therefore, an inhibitor bound to the ATP-binding
site of the native Hsp90 could destabilize dimer. That might explain
preferential formation of the dimers composed of the two molecules
of the inhibitor-resistant Hsp90.
The C-domain of the hybrid Hsp90 determines which isoform of the
native Hsp90 may form heterodimer with a given hybrid Hsp90.
Fig. 5.Hsp90α activity in yeast depends onAha1. AHA1 andHCH1 geneswere disrupted in
the yeast strains that expressed Hsp90α or Hsp90β. The growth of these strains wasmea-
sured in YPDmedium at 30 °C using Bioscreen Cmicroplate reader (Oy Growth Curves Ab
Ltd). Plot presents generation times and SD calculated from four experiments.
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(H4IT, H6IT, H7IT, and H10IT) may form heterodimers with native
Hsp90α. Similarly, Hsp90β Ile123Thr and hybrids H3IT, H5IT, H8IT, and
H9IT may form heterodimers with native Hsp90β. The resulting bias
should be similar for all hybrids that dimerize with the same native
Hsp90 isoform and should decrease observed differences in Aha1 bind-
ing rather than enhance them. Minor inﬂuences of the native Hsp90
cannot be excluded in some of the results. For example, low binding of
Aha1 to H8, compared to H7, may be caused by heterodimerization
with native Hsp90β and rather high binding of Aha1 to H6, compared
to H5, could be explained by formation of heterodimers with native
Hsp90α. However, even in these cases the effect of M-domain clearly
prevails because binding of Aha1 to the hybrids with the αM-domain
is stronger.
The Hsp90α Ile128Thr and Hsp90β Ile123Thr aa substitutions, located
in the N-domains of these proteins, greatly increase afﬁnity of the mu-
tant Hsp90 to Aha1, which could raise concerns of possible artifacts
caused by these mutations [31]. However, these mutations increase
Aha1 binding to bothHsp90 isoforms [53]. Therefore, difference in afﬁn-
ity for Aha1 demonstrated by the Hsp90α and Hsp90β M-domains is
unlikely to result from these single aa substitutions. Two distinct obser-
vations validate the results obtained with Hsp90 17-AAG-resistant mu-
tants. Namely, (i) Cdc37,which is a co-chaperone that interactswith the
N-domain, bound to both Hsp90α Ile128Thr and Hsp90β Ile123Thr with
equal afﬁnity [54]. (ii) Non-mutated Hsp90α bound in vivo Aha1 with
higher afﬁnity when compared to binding with Hsp90β.
There are two homologues of human AHA1 in the yeast genome,
called AHA1 and HCH1. The longer protein encoded by AHA1 corre-
sponds to the full-length human protein, whereas HCH1 encodes a
shorter protein that corresponds to the N-domain of the human Aha1.
Yeast Aha1 is only 23% identical to its human homolog and Hch1 is
even less conserved [41]. Deletion of either gene has no effect on yeast
grown at 30 °C and becomes detrimental only when cells are exposed
to elevated temperatures and are forced to respiratory growth [49].
These results suggest that yeast Hsp90 proteins can function effectively
without aid from these co-chaperones and the cooperation between
Hsp90 and Aha1 or Hch1 becomes necessary only under stress caused
by high temperature or growth conditions. Our experiments demon-
strated that deletion of AHA1 or HCH1 genes had little effect on yeasts
expressing human Hsp90β. This isoform, like its yeast homolog, does
not depend on the ATPase stimulating co-chaperones under non-
stressful conditions whereas Hsp90α under the same conditionsrequires Aha1 for full activity. In the yeast cell for each Aha1 or Hch1
molecule, there are at least 12 Hsp90 dimers (counting together
Hsc82 and Hsp82) [55]. If the expression rates of Aha1 and Hsp90 in
human cells are similar, Hsp90 must compete for the available co-
chaperone. The experiments in yeast suggest that chaperoning activity
of Hsp90α is more dependent on Aha1 than activity of Hsp90β. There-
fore, the high afﬁnity of Hsp90α for Aha1 observed in human cells
may be an adaptation that allows this isoform to function effectively
in a presence of limiting quantities of the co-chaperone. Hch1 has no
human homolog, is only 36% identical to the yeast Aha1, and is a weak
stimulator of the yeast Hsp90 ATPase compared to Aha1. Moreover, de-
spite their homology, Aha1 and Hch1 seem to interact with Hsp90 in a
different way [56]. Therefore, Hch1 may not be able to interact with
human Hsp90s or may not stimulate their ATPase activity. That may
explain why HCH1 deletion does not affect growth of yeast that express
human Hsp90 as a sole source of this protein.
CIAP1 is the speciﬁc substrate for Hsp90β [24]. An interaction with
Hsp90β stabilizes cIAP1 and increases its cellular concentration.
Client proteins are believed to interact with the middle domain of
Hsp90 [2,57]. Therefore, we expected that cIAP1 would be chaperoned
more efﬁciently by the hybrids that contain the middle domain of this
isoform. Surprisingly, the high expression level of cIAP1 depended on
the presence of N-terminal but not M-domain of Hsp90β in the hybrid
gene.
Structural analysis of the Hsp90-Cdc37-Cdk4 complex suggested
that the N-domain of Hsp90 contributes to the binding of the client
kinase Cdk4 [58]. Similarly, cIAP1 may also interact directly with both
N and M-domain of Hsp90, and the preference of cIAP1 for Hsp90β
may result from some small differences in structure of the highly
homologous α and β N-domains.
In conclusion, we demonstrated for the ﬁrst time that Aha1 co-
chaperone interacts preferentially with Hsp90α and that this speciﬁc
interaction is mediated by the M-domain of Hsp90. We also provided
evidence for the speciﬁc interaction of cIAP1 with the N-domain of
Hsp90β. Aha1 and cIAP1 use different fragments of Hsp90 to discrimi-
nate between Hsp90α and Hsp90β, suggesting that functional differ-
ences between Hsp90 isoforms may depend on differences dispersed
among many fragments of this protein. Speciﬁcity of the interaction
with a particular protein may depend on a set of structural features
unique for this protein. Our results proved also that using 17-AAG-resis-
tant mutants as an alternative to the conventional techniques used for
protein expression silencing facilitates functional Hsp90 analysis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.11.026.Acknowledgments
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